Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,762 across all filing types
Latest filing 2024-06-13 Regulatory Filings
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Intimation of loss of share certificate
Regulatory Filings
2024-06-13 English
Loss of Share Certificates
Regulatory Filings
2024-06-13 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement addressed to stock exchanges under SEBI Listing Obligations and Disclosure Requirements. It informs about a USFDA Pre-Approval Inspection and issuance of Form 483 observations at the company's manufacturing facility. There is no detailed financial data, no full report attached, and the document is under 5,000 characters. It is an update on regulatory inspection results, not a full audit report or annual report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2024-06-12 English
Intimation under regulation 30 of SEBI (LODR) regulation, 2015
Regulatory Filings Classification · 95% confidence The document is a short notice addressed to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about a USFDA Pre-Approval Inspection and issuance of Form 483 with observations. The document does not contain financial data, detailed reports, or results but is an update on regulatory inspection findings. It is an announcement of a material event rather than a full report or detailed filing. The length is short (1942 characters), and it serves as a regulatory disclosure to stock exchanges. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance announcements and regulatory updates that do not fit other specific categories.
2024-06-12 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the stock exchange listing department announcing a new business agreement: Torrent Pharmaceuticals entering into a non-exclusive patent licensing agreement with Takeda Pharmaceuticals to commercialize a novel gastrointestinal drug in India. The content is a press release about a strategic partnership and product commercialization, not a financial report, earnings release, or regulatory filing. It does not contain financial statements, voting results, management changes, or legal proceedings. The document is an announcement of a corporate development related to licensing and commercialization, which fits best under Capital/Financing Update (CAP) as it relates to business growth and strategic agreements impacting company operations and potentially capital structure or market position. The document length is 3770 characters, which is short and typical for an announcement rather than a detailed report. Therefore, the most appropriate classification is CAP with high confidence.
2024-06-05 English
Torrent Pharmaceuticals Enters into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceuticals to Commercialize its Novel Gastrointestinal Drug in India
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Torrent Pharmaceuticals has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceuticals to commercialize a novel gastrointestinal drug in India. It contains no financial statements, no regulatory certifications, no voting results, no management or board changes, and no detailed financial or operational data. The document is an announcement of a business development or partnership rather than a financial report or regulatory filing. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category that covers miscellaneous filings that do not fit other specific categories.
2024-06-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.